Frontlight ResearchEarly access
CompletedNo phase
Tiara™ Transcatheter Mitral Valve Replacement Study
Key facts
- Who runs it
- Shockwave Medical, Inc.
- Where
- Germany, Israel, Italy, Netherlands, Spain, and United Kingdom20 sites in 6 countriesChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 157 people enrolled
- Started
- 8 Mar 2017
- Ended
- 6 Aug 2024
- Type of study
- Interventional
- Treatments tested
- TIARA valve and transapical delivery system
- Record updated
- 29 September 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Severe mitral regurgitation
- High surgical risk for open mitral valve surgery
- Subject meets anatomical eligibility criteria
Who cannot take part
- Previous cardiac procedures: any mitral valve replacement surgery and cardiac transplant
- Unsuitable cardiac structure
- Clinically significant untreated Coronary Artery Disease (CAD)
- Documented bleeding or coagulation disorders
- Active infections requiring antibiotic therapy
- Deemed too frail by objective frailty assessments
- Subjects on chronic dialysis
- Pregnant or planning pregnancy within next 12 months
- Subjects with a life expectancy less than 12 months
This trial has no sites in United States.
It has sites in 6 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
To evaluate the safety and performance of the Neovasc Tiara Mitral Transcatheter Heart Valve with the Tiara Transapical Delivery System.
The group in the trial
- TreatmentTreatment being tested
Transcatheter mitral valve replacement with the TIARA valve and transapical delivery system
Treatment: TIARA valve and transapical delivery system
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Tiara™ Transcatheter Mitral Valve Replacement Study (TIARA-II)
- Record updated
- 29 September 2025